Leutenegger M
Nouv Presse Med. 1980 Oct 30;9(40):2985-9.
probucol is a new hypolipaemic agent which differs from similar drugs in current use by its chemical structurae and, probably, by its mode of action. Its predominantly cholesterol-lowering activity and its lack of serious side-effects make it a valuable product for the treatment of type IIa hypercholesterolaemia and of type II b mixed dyslipaemia. Whether or not it can be advantageously combined with other cholesterol-lowering agents in resistant hypercholesterolaemia remains to be determined. As with most drugs of this kind available at present, randomized prospective trials are required to demonstrate the efficacy of probucol in preventing atheroma and its safety in long-term usage.
普罗布考是一种新型降血脂药,其化学结构与目前使用的同类药物不同,作用方式可能也不同。它主要具有降低胆固醇的活性,且没有严重的副作用,这使其成为治疗IIa型高胆固醇血症和IIb型混合性血脂异常的有价值的药物。它是否能与其他降胆固醇药物有效联合用于治疗难治性高胆固醇血症仍有待确定。与目前现有的大多数此类药物一样,需要进行随机前瞻性试验来证明普罗布考在预防动脉粥样硬化方面的疗效及其长期使用的安全性。